Compare MD & APLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MD | APLS |
|---|---|---|
| Founded | 1979 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Hospital/Nursing Management | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 2.2B |
| IPO Year | 1996 | 2015 |
| Metric | MD | APLS |
|---|---|---|
| Price | $20.80 | $17.07 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 4 | 21 |
| Target Price | $20.00 | ★ $31.65 |
| AVG Volume (30 Days) | 728.5K | ★ 1.9M |
| Earning Date | 05-05-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 263.03 | 112.50 |
| EPS | ★ 1.94 | 0.20 |
| Revenue | ★ $1,913,849,000.00 | $1,003,782,000.00 |
| Revenue This Year | $3.72 | N/A |
| Revenue Next Year | $2.62 | $18.21 |
| P/E Ratio | ★ $10.56 | $84.90 |
| Revenue Growth | N/A | ★ 28.46 |
| 52 Week Low | $11.84 | $16.10 |
| 52 Week High | $24.99 | $30.48 |
| Indicator | MD | APLS |
|---|---|---|
| Relative Strength Index (RSI) | 57.19 | 29.92 |
| Support Level | $20.72 | N/A |
| Resistance Level | $21.98 | $20.65 |
| Average True Range (ATR) | 0.61 | 0.65 |
| MACD | 0.18 | -0.04 |
| Stochastic Oscillator | 76.58 | 8.08 |
Pediatrix Medical Group Inc provides physician services to hospitals, intensive care units, and other medical units. The services provided by the company include maternal care for expectant mothers, intensive care for premature babies, cardiology care for infants suffering from heart defects, and anesthesia care during surgeries, among others. The company operates only under one segment which provides physician services including newborn, maternal-fetal, and other pediatric subspecialty care. It generates majority of the revenue through neonatology and other pediatric subspecialties.
Apellis Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade. Currently it has two marketed drugs that target C3, the central protein in the complement cascade: SYFOVRE (pegcetacoplan injection) and EMPAVELI (pegcetacoplan).